Purinergic Dysfunction in Pulmonary Arterial Hypertension by Cai, Z.Y. et al.
Journal of the American Heart Association
J Am Heart Assoc. 2020;9:e017404. DOI: 10.1161/JAHA.120.017404 1
 
CONTEMPORARY REVIEW
Purinergic Dysfunction in Pulmonary Arterial 
Hypertension
Zongye Cai , MD, PhD; Ly Tu, PhD; Christophe Guignabert, PhD; Daphne Merkus , PhD;  
Zhichao Zhou , MD, PhD
ABSTRACT: Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by increased pulmonary arterial 
pressure and pulmonary vascular resistance, which result in an increase in afterload imposed onto the right ventricle, leading 
to right heart failure. Current therapies are incapable of reversing the disease progression. Thus, the identification of novel and 
potential therapeutic targets is urgently needed. An alteration of nucleotide- and nucleoside-activated purinergic signaling has 
been proposed as a potential contributor in the pathogenesis of PAH. Adenosine-mediated purinergic 1 receptor activation, 
particularly A2AR activation, reduces pulmonary vascular resistance and attenuates pulmonary vascular remodeling and right 
ventricle hypertrophy, thereby exerting a protective effect. Conversely, A2BR activation induces pulmonary vascular remod-
eling, and is therefore deleterious. ATP-mediated P2X7R activation and ADP-mediated activation of P2Y1R and P2Y12R play a 
role in pulmonary vascular tone, vascular remodeling, and inflammation in PAH. Recent studies have revealed a role of ecto-
nucleotidase nucleoside triphosphate diphosphohydrolase, that degrades ATP/ADP, in regulation of pulmonary vascular re-
modeling. Interestingly, existing evidence that adenosine activates erythrocyte A2BR signaling, counteracting hypoxia-induced 
pulmonary injury, and that ATP release is impaired in erythrocyte in PAH implies erythrocyte dysfunction as an important trig-
ger to affect purinergic signaling for pathogenesis of PAH. The present review focuses on current knowledge on alteration of 
nucleot(s)ide-mediated purinergic signaling as a potential disease mechanism underlying the development of PAH.
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Pulmonary arterial hypertension (PAH) is defined as an elevation of mean pulmonary arterial pres-sure (PAP) >20  mm  Hg, with pulmonary arterial 
wedge pressure <15 mm Hg and pulmonary vascular 
resistance (PVR) >3 wood units at rest based on right 
heart catheterization at sea level.1 PAH is a progres-
sive disorder characterized by pulmonary endothelial 
dysfunction, increased pulmonary vascular tone, and 
pulmonary vascular remodeling, with muscularization, 
thickening, and occlusion of the pulmonary (micro)vas-
culature, leading to an increase in afterload of the right 
ventricle (RV), and eventually death caused by right 
heart failure.2 Pulmonary vascular remodeling involves 
aberrant proliferation, hyperplasia, and/or hypertrophy 
of pulmonary artery endothelial cells (PAECs) and/or 
microvascular endothelial cells (ECs), pulmonary ar-
tery smooth muscle cells (PASMCs), and fibroblasts. 
In addition, perivascular inflammatory foci, consisting 
of infiltrates with antigen-presenting cells and immune 
cells, such as macrophages and T and B lymphocytes, 
have been shown in PAH.3 Current therapies are prin-
cipally aimed at reversing the increase in vascular tone 
and may reduce smooth muscle proliferation and mus-
cularization of the distal vasculature.4 However, prog-
nosis of PAH is still poor, with a 5-year survival of 59%.5 
Therefore, more investigations are needed to identify 
novel underlying mechanisms in PAH to develop new 
therapies.
Recent findings have revealed that there is an al-
teration of nucleot(s)ide-mediated purinergic signaling 
in the pulmonary vasculature, which may contribute to 
the development and progression of P(A)H. Many cell 
types, such as ECs, immune cells, and erythrocytes, 
can produce nucleotides (such as ATP and UTP) and 
Correspondence to: Zhichao Zhou, MD, PhD, J8: 20, BioClinicum, Division of Cardiology, Department of Medicine, Karolinska University Hospital, Karolinska 
Institutet, Stockholm 17176, Sweden. E-mail: zhichao.zhou@ki.se or zhzhou2015@gmail.com
For Sources of Funding and Disclosures, see page 11.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.  This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and 
is not used for commercial purposes. 
JAHA is available at: www.ahajournals.org/journal/jaha
D
ow
nloaded from
 http://ahajournals.org by on O
ctober 26, 2020
J Am Heart Assoc. 2020;9:e017404. DOI: 10.1161/JAHA.120.017404 2
Cai et al Purinergic Dysfunction and Pulmonary Hypertension
nucleosides (such as adenosine), which activate puri-
nergic receptors (PRs) to exert biological functions.6–8 
Activation of purinergic signaling has been demon-
strated to play an essential role in cardiovascular ho-
meostasis,9–11 whereas there is increasing evidence 
to suggest that purinergic signaling may also play an 
important role in P(A)H by modulating vascular tone, re-
modeling, permeability, and inflammation.12–15 Therefore, 
nucleoti(s)ide-mediated purinergic signaling may serve 
as a potential target for the treatment of P(A)H. In the 
present review, we summarize available information on 
purinergic dysfunction in both patients with PAH and 
animal models of pulmonary hypertension (PH).
ACTIVATION AND REGULATION OF 
PURINERGIC SIGNALING IN PAH
Nucleotides (ATP, ADP, UTP, and UDP), nucleosides 
(adenosine), and even dinucleotides (eg, Up4A) could 
be released directly or indirectly via ectonucleoti-
dases from ECs, adventitial nerves, and circulating 
cells (including platelets, immune cells, and erythro-
cytes) in response to both physiological and patho-
logical stimuli. The release of ATP from erythrocytes 
particularly occurs under hypoxic conditions and is 
increasingly recognized to play a role in regulation 
of tissue perfusion.16,17 Homeostasis between ex-
tracellular nucleotides and adenosine is governed 
by various ectonucleotidases. Ectonucleotidases 
are divided into 4 major families: (1) nucleoside 
triphosphate diphosphohydrolase (also known 
as CD39), (2) ecto-5’-nucleotidase, (3) nucleotide 
pyrophosphatase/phosphodiesterase, and (4) alka-
line phosphatases.9 For example, once ATP is re-
leased extracellularly, ATP is degraded to ADP and 
AMP through the continuous action of CD39. Ecto-
5’-nucleotidase can further phosphohydrolyze AMP 
to adenosine (Figure 1).
Alterations in ectonucleotidases regulating the pu-
rinergic signaling have been reported in PAH. CD39, 
one of the ectonucleotidases hydrolyzing ATP and ADP 
to AMP, was found to be higher on circulating endo-
thelial microparticles from patients with idiopathic PAH 
(iPAH).18 On the contrary, CD39 expression was signifi-
cantly downregulated in the endothelium of pulmonary 
small arteries from patients with iPAH.13,19 Similarly, both 
expression and activity of CD39 were decreased in cul-
tured PAECs derived from patients with PAH compared 
with healthy subjects.19 The downregulation of CD39 
in the pulmonary vasculature may alter the balance 
between ATP and adenosine, thereby affecting puri-
nergic signaling in PH. Indeed, the plasma adenosine 
concentration is lower in the pulmonary circulation in 
patients with PAH compared with the high plasma ad-
enosine levels in healthy subjects (Table).20,21 Similarly, 
in newborn lambs with hypoxia-induced PH, baseline 
plasma adenosine levels in pulmonary circulation and 
left atrium were significantly lower than in normoxic con-
trols (Table).22 Suppression of CD39 in cultured PAECs 
resulted in a phenotypic switch toward apoptosis-resis-
tant PAECs19 and may thereby contribute to pulmonary 
vascular remodeling. Indeed, in addition to the markedly 
elevated ATP/adenosine ratio, hypoxic CD39 knock-
out mice demonstrated higher PAP, more pulmonary 
vascular remodeling, more RV hypertrophy, and a pro-
thrombotic phenotype compared with normoxic con-
trols (Table).13 Of note, systemic reconstitution of ATPase 
and ADPase enzymatic activities through continuous 
administration of apyrase dramatically decreased PAP 
in hypoxic CD39 knockout mice to levels found in hy-
poxic wild-type mice (Table).13 Altogether, these ob-
servations indicate that CD39 is an important enzyme 
regulating pulmonary vascular remodeling and suggest 
that therapeutic modulation of the balance between 
adenosine and ATP may directly affect pulmonary vas-
cular remodeling (Figure 1). Interestingly, the activity of 
CD39 in both cultured PAECs and PAECs isolated from 
monocrotaline-induced PH rats can be potentiated by 
apelin (Table), a known regulator of pulmonary vascular 
homeostasis that is decreased in patients with PAH,23,24 
suggesting that the therapeutic efficacy of apelin in an-
imal models of PAH may be mediated, at least in part, 
through modulation of purinergic signaling.19
The biological effects of nucleot(s)ides are usually 
mediated via the activation of PRs, which consist of 2 
subfamilies, purinergic receptor 1 (P1R) and purinergic 
receptor 2 (P2R).54,55 The P1R subfamily (all metabo-
tropic; also known as adenosine receptors) includes 
Nonstandard Abbreviations and Acronyms
CD39 nucleoside triphosphate 
diphosphohydrolase
EC endothelial cell
iPAH idiopathic PAH
PAP pulmonary arterial pressure
NECA nonselective adenosine receptor agonist 
5’-(N-ethylcarboxamido) adenosine
P1R purinergic receptor 1
P2R purinergic receptor 2
PAEC pulmonary artery endothelial cell
PAH pulmonary arterial hypertension
PASMC pulmonary artery smooth muscle cell
PH pulmonary hypertension
PR purinergic receptor
ROCK Rho kinase
SMC smooth muscle cell
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4 subtypes: A1R, A2AR, A2BR, and A3R. The P2R sub-
family has 2 subgroups, P2XRs and P2YRs.55,56 The 
ionotropic P2XRs include 7 P2XRs (P2X1-7R), and the 
metabotropic P2YRs contain 8 P2YRs (ie, P2Y1R, 
P2Y2R, P2Y4R, P2Y6R, P2Y11R, P2Y12R, P2Y13R, 
and P2Y14R).
57 P1Rs can be activated by adenosine, 
whereas P2Rs are capable of mediating responses to 
several nucleotides and have overlapping ligand pref-
erences. P2X1-7Rs and P2Y11R are mainly activated 
by ATP; P2Y1R, P2Y12R, and P2Y13R are activated by 
ADP, whereas P2Y1R is sensitive to both ATP and ADP. 
Moreover, P2Y2R and P2Y4R are preferably activated 
by UTP, whereas P2Y6R preferably responds to UDP 
(Figure  2).55 On stimulation by different extracellu-
lar nucleot(s)ides, PR-mediated signaling is initiated, 
which results in various responses, including platelet 
aggregation, cell proliferation, angiogenesis, immune 
responses, and vascular tone regulation.8,55,58–60 
Although some heterogeneity of the PR expression 
and distribution was found between species,55,58,59 
all 4 adenosine receptors were found in the lungs 
of mice and humans,61 and P2Rs are located in the 
pulmonary arteries of various species. Thus, P2X1R, 
P2X2R, P2X4R, P2X5R, P2X7R, P2Y1R, P2Y2R P2Y6R, 
and P2Y11R are expressed in isolated PAECs, whereas 
P2X1R, P2X3R, P2X4R, P2X7R, P2Y1R, P2Y2R, and 
P2Y12R have been found in the intact pulmonary vas-
culature (Figure 2).14,19,43,44,62
PURINERGIC DYSFUNCTION IN 
PULMONARY VASCULAR TONE AND 
REMODELING
Alterations in P1R Signaling in PAH
Plasma adenosine concentrations are lower in pa-
tients with PAH than in healthy subjects,20,21 and the 
response of pulmonary vasculature to adenosine 
and P1R agonists is altered in PAH, indicating a po-
tential deficiency in adenosine-mediated purinergic 
signaling in PAH. The pulmonary vasodilator effect 
of adenosine in patients with PH appears to be de-
pendent on cause of the disease. Thus, in patients 
with PH after cardiac surgery, central venous infusion 
of adenosine not only induced pulmonary vasodila-
tion with significant decreased PAP and PVR, but 
also induced an increase in cardiac output with mean 
arterial pressure being unaffected.25 Intravenous in-
fusion of a high dose of adenosine decreased PAP, 
PVR, and systemic arterial pressure in around 50% 
of patients with severe PAH secondary to a congeni-
tal heart defect.26 Intravenous adenosine infusion de-
creased PAP in 6 of 9 neonates with persistent PH 
who received inhaled NO (Table).27 Conversely, when 
adenosine was administered in patients with iPAH, 
only ≈10% of patients exhibited significant decreases 
in mean PAP and PVR.63 In children with iPAH, 3 of 
15 cases did respond to adenosine with a reduction 
in PAP.64
When testing a potential pulmonary vasodilator 
effect of adenosine, one should carefully consider 
dose and route of administration as adenosine has 
a short half-life of 5 to 10  seconds.65 Hence, infu-
sion into the pulmonary circulation is preferred as 
adenosine then likely has a (more) selective effect on 
pulmonary vasculature, because of its higher con-
centrations in the pulmonary circulation compared 
with the systemic circulation. Indeed, adenosine in-
fusion via the right atrium (0.01–2.5 µmol/kg per min-
ute) in hypoxic lambs has a pulmonary vasodilator 
effect, evidenced by a decrease in PAP and PVR at 
all doses tested.22 A similar effect was present in nor-
moxic lambs, but required higher doses of 0.15 to 
2.5 µmol/kg per minute, than in the hypoxic lambs,22 
suggesting that hypoxia sensitizes the response of 
Figure 1. Nucleotides and adenosine regulation in pulmonary hypertension.
Homeostasis between extracellular nucleotides and adenosine is governed by ectonucleotidases, 
including nucleoside triphosphate diphosphohydrolase (CD39), ecto-5’-nucleotidase (CD73), nucleotide 
pyrophosphatase/phosphodiesterase (NPP), and adenosine deaminase. CD39 phosphohydrolyzes ATP 
and ADP to AMP, which is dephosphorylated to adenosine by CD73. Adenosine can be further degraded by 
adenosine deaminase to inosine. In pulmonary hypertension, CD39 is downregulated and adenosine deaminase 
is upregulated, resulting in low adenosine levels in the pulmonary vasculature (generated by Biorender).
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pulmonary vasculature to adenosine. The systemic 
effects of adenosine (decrease in aortic pressure and 
systemic vascular resistance, increase in heart rate 
and cardiac output) were observed in both normoxic 
and hypoxic lambs with doses ≥0.3  µmol/kg per 
minute (Table).22,45 These results suggest that lower 
doses of adenosine directly reduce the PAP by re-
ducing PVR, whereas at higher doses the decrease 
in PAP is limited by the increase in cardiac output. 
This pulmonary vasodilator effect of adenosine in 
hypoxic lambs was attenuated by prior treatment of 
nonselective P1R antagonist aminophylline,22 indicat-
ing that the pulmonary vasodilator effect is mediated 
via P1R.
Further evidence for alterations of P1R in the ad-
enosine-mediated regulation of vascular function in 
pulmonary vasculature has been shown in endo-
thelium-denuded pulmonary arteries isolated from 
guinea pigs, in which the nonselective adenosine 
receptor agonist 5’-(N-ethylcarboxamido) adenosine 
(NECA) produced concentration-dependent con-
traction.50 The vasoconstrictor response to NECA 
was converted to relaxation in the presence of cy-
clooxygenase inhibition.50 Interestingly, although ex-
posure of these vessels to hypoxia did not alter the 
contractile response to NECA under baseline con-
ditions, a biphasic response, contraction followed 
by relaxation, was observed in response to NECA 
in the presence of cyclooxygenase inhibition. This 
initial vasoconstrictor effect was prevented by A1R 
blockade (Table).50 This study indicates that, in ad-
dition to the cyclooxygenase-dependent pulmonary 
vasoconstrictor effect of adenosine, exposure to 
hypoxia alters adenosine signaling and induces an 
A1R-mediated vasoconstrictor effect.
Long-term subcutaneous infusion of adenosine, 
the nonselective P1R agonist NECA, or the selective 
A1R agonist N6-cyclopentyladenosine into rats with 
chronic hypoxia-induced PH significantly reduced 
PAP, plasma renin activity, and angiotensin II levels, 
as well as endothelin-1 levels, and increased NO 
levels, thereby counteracting the effects of chronic 
hypoxia.37 Of note, adenosine and NECA but not 
N6-cyclopentyladenosine also significantly attenu-
ated the pulmonary vascular remodeling induced by 
chronic hypoxia (Table).37 These data, showing that 
A1R agonism only partially mimicked the beneficial 
effects of P1R agonism, are consistent with a low 
A1R expression in the (healthy) human pulmonary 
vasculature,66 and suggest that other P1Rs than the 
A1R are also involved.
The involvement of A2AR in the development of PH 
has been characterized in A2AR knockout mice. The 
A2AR knockout mice already show hemodynamic 
and histological characteristics of PAH, as evidenced 
by increased pulmonary vascular remodeling with 
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excessive vascular cell (PAEC and PASMC) prolifer-
ation and hypertrophy in pulmonary resistance ves-
sels, as well as increased collagen deposition and an 
increased RV pressure even in the absence of other 
triggers of PAH.39 Exposure of these mice to chronic 
hypoxia exacerbates hypertrophy and increased 
cell proliferation in pulmonary resistance vessels in 
the A2AR knockout mice, resulting in further eleva-
tions in RV pressure and RV hypertrophy (Table).39 
Pulmonary vascular remodeling in A2AR knockout 
mice was accompanied by increased mRNA and 
protein expression for Ras homolog gene family 
member A and Rho kinase (ROCK) 1 (Table), with lo-
calization of ROCK1 protein in PAECs and PASMCs, 
bronchial, and alveolar epithelial cells.40 Activation 
of the Ras homolog gene family member A/ROCK 
pathway has been proposed to play a key role in reg-
ulation of smooth muscle contraction and prolifera-
tion in PH.67 Once activated, these pathways not only 
activate Ca2+/calmodulin-dependent myosin light 
chain kinase (contraction) but also inactivate Ca2+-
independent myosin light chain phosphatase (relax-
ation). As these 2 components balance each other in 
the healthy vasculature to maintain a low level of pul-
monary vascular tone, an imbalance induces vaso-
constriction. In PH, activation of Rho kinase induces 
Ca2+ signaling, which further activates Ras homolog 
gene family member A/Rho kinase, leading to a vi-
cious circle of vascular contraction and remodeling.68 
Taken together, these observations suggest that the 
loss of adenosine in PAH and consequent reduction in 
A2AR activation may trigger the Rho/ROCK signaling 
pathway. Considering a potential role of A2AR in 
suppressing P(A)H, 2 new A2AR agonists have been 
developed and tested in animal models of PH. The 
A2AR agonist LASSBio-1386, administered 2 weeks 
after monocrotaline treatment, significantly reduced 
the proliferative changes in the pulmonary arteri-
oles in a rat model of monocrotaline-induced PH.34 
Similarly, another A2AR agonist, LASSBio-1359, abol-
ished the increased RV overload and reduced vessel 
wall hypertrophy, demonstrating satisfactory efficacy 
through long-term oral administration in monocro-
taline-induced PH, with no adverse effect on the sys-
temic vasculature.35 Of note, the impaired pulmonary 
endothelial function reflected by the reduced acetyl-
choline-induced NO-dependent relaxation in isolated 
pulmonary arteries was markedly attenuated in rats 
with PH treated with LASSBio-1386 or LASSBio-1359 
(Table).34,35 More recently, the same group showed 
that combination therapy with a 5 times lower dos-
age of LASSBio-1359 than previously used and the 
phosphodiesterase 5 inhibitor sildenafil, but not the 
monotherapy with either of them, ameliorated all the 
PH-associated abnormalities, as observed in their 
previous studies.31 Therefore, activation of A2AR is a 
promising additional tool for the treatment of PAH.
Although activation of A2AR may be beneficial in 
PAH, activation of the A2BR may result in pulmonary 
vascular remodeling in P(A)H in both human and an-
imal studies. An upregulation of the A2BR in human 
lungs was found in patients with various forms of PH, 
including PAH,28 PH secondary to idiopathic pulmo-
nary fibrosis compared with those without PH,69 and 
Figure 2. The ligand, expression and location of purinergic receptors.
Different nucleo(s)tides activate their preferable purinergic receptors to exert vascular biological influence 
(top panel). Distribution and location of key purinergic receptors in pulmonary vasculature (bottom panel). 
In pulmonary vasculature, all 4 adenosine receptors are present. P2X1, P2X2, P2X4, P2X5, P2X7, P2Y1, 
P2Y2, P2Y6, and P2Y11 are expressed in endothelial cells, whereas P2X1, P2X3, P2X4, P2X7, P2Y1, P2Y2, and 
P2Y12 have been found in the intact pulmonary vasculature (generated by Biorender).
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PH secondary to chronic obstructive pulmonary dis-
ease.70 A2BR expression was increased specifically 
in PASMCs from patients with iPAH compared with 
controls (Figure 3).28 A functional role for the A2BR was 
shown by pharmacological inhibition of A2BR using 
the antagonist GS-6201 as well as genetic deletion of 
A2BR, which attenuated the fibroproliferative and vas-
cular remodeling processes that contribute to PH in 
the lung of mice with bleomycin-induced PH and lung 
fibrosis.51 The detrimental role of A2BR activation was 
narrowed down to the smooth muscle cell (SMC) by 
specific depletion of the A2BR in SMCs in mice, which 
protected these mice from the development of PH and 
pulmonary vascular remodeling in response to expo-
sure to bleomycin or SUGEN with hypoxia.28 Specific 
A2BR depletion in SMCs also inhibited the produc-
tion of several proremodeling mediators in these PH 
models, including interleukin-6), hyaluronan synthase 
2, and transglutaminase 2.28 Elevation of interleukin-6 
and endothelin-1, which are implicated as important 
mediators in pulmonary vascular remodeling in PH, 
was also attenuated by pharmacological inhibition and 
genetic deletion of A2BR.
51 A direct role for A2BR ac-
tivation in these processes was confirmed by exper-
iments showing that adenosine receptor stimulation 
promoted interleukin-6 and endothelin-1 release from 
both PAECs and PASMCs, which could be inhibited 
by a selective A2BR antagonist.
51 Furthermore, the cul-
ture medium from A2BR-activated PAECs was able to 
promote proliferation of PASMCs.51 Taken together, 
these findings suggest a crucial role of A2BR in pul-
monary vascular remodeling in PAH (Table). Targeting 
A2BR may serve as potential therapeutic strategy for 
the abnormal remodeling of the pulmonary vasculature 
associated with PAH.
Altogether, these findings support the potential 
of targeting P1R signaling to ameliorate PAH. To our 
knowledge, P1R subtype distribution in the pulmo-
nary vasculature in patients with PAH is unclear. To 
date, most research has focused on A2R, whereas 
the role of A1R and A3R in pulmonary vascular re-
modeling is not fully understood. As the receptor ex-
pression and distribution may change in pathological 
conditions, further characterization of the P1R sub-
types in the pulmonary vasculature from patients with 
PAH is required. Cross talk among PRs has been re-
ported in other vascular beds. For instance, there is 
an upregulation of A2BR in coronary arteries of A2AR 
knockout mice.71 However, in these global knockout 
mice, the adenosine receptor expression and func-
tion were not examined in pulmonary tissue. It could 
be speculated that the pulmonary pathological fea-
tures observed in A2AR knockout mice may partially 
be attributed to the upregulation of A2BR.
39 On the 
Figure 3. Purinergic receptor as the potential therapeutic target for the treatment of pulmonary 
hypertension.
In pulmonary hypertension, A2B, P2X7, P2Y1, P2Y11, and P2Y12 receptors are upregulated (red) and A2A 
receptors are downregulated (white) in the pulmonary vasculature. The potential receptors (A2A, A2B, and 
P2X7) as therapeutic targets are highlighted with the capsule symbols, whereas the A2AR may be involved 
in initiation of the disease (generated by Biorender).
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basis of experimental animal studies, A2AR activation 
and A2BR inhibition both seem to be promising strat-
egies for reversing pulmonary vasoconstriction in 
the treatment of PAH.12 Selective A2AR agonism has 
been used in clinical studies mainly for the evaluation 
of cardiac function and detection of coronary artery 
disease.72,73 Stress tests have also been performed 
in patients with PAH using the A2AR agonist regade-
noson and showed no major adverse effects (Table), 
suggesting that such intervention is safe.29 However, 
clinical trials are needed in the future to further char-
acterize the therapeutic role of A2AR activation in the 
treatment of patients with PAH.
Alterations in P2R Signaling in PAH
The role of P2R activation in the pulmonary vascula-
ture has been addressed in different P(A)H models. 
Depending on the agonist and, most likely, the P2R 
involved, P2R activation can cause either pulmonary 
vasoconstriction or vasodilation. In swine with acute 
hypoxia-induced PH, blockade of P2Y1R with the se-
lective antagonist MRS2500 decreased PAP and PVR, 
whereas cardiac output was unchanged, while target-
ing P2Y12R with cangrelor reduced PAP secondary to 
a decrease in cardiac output, with no change in PVR.43 
Infusion of ADP increased both PAP and PVR, which 
was abolished by P2Y1R blockade and P2Y12R block-
ade (Figure 3).43 In contrast to the vasoconstriction in-
duced by ADP, ATP induced pulmonary vasodilation, 
as evidenced by significant decreases in PAP and PVR 
in newborn lambs. The pulmonary vasodilator effect 
was not affected by the nonselective P1R antago-
nist theophylline, suggesting involvement of P2Rs.46 
Furthermore, the sensitivity of pulmonary vasculature 
from hypoxic newborn lambs to ATP infusion (0.01–
0.3 μmol/kg per minute via right atrium) was greater 
than that from normoxic newborn lambs46 as vasodila-
tion occurred at a lower dose of ATP. In both normoxic 
and hypoxic lambs, the systemic effect of ATP only oc-
curred at dosages >0.3 μmol/kg per minute.45,46 ATP 
infused into the pulmonary artery also significantly re-
duced mean PAP and PVR in young lambs, with PH 
induced by the thromboxane analogue U46619 with-
out affecting mean arterial pressure.74 In swine with 
meconium aspiration-induced PH, ATP infusion at 
low dose (0.02–0.08 μmol/kg per minute) selectively 
decreased PAP and PVR; a reduction in systemic re-
sistance was only observed with higher ATP dosage 
(0.32–0.8 μmol/kg per minute).47 Similarly, ATP-MgCl2 
infusion (at the optimal dose of 0.1 mg/kg per minute) 
reduced mean PAP and PVR without affecting mean 
arterial pressure in piglets with hypoxia-induced PH.30 
ATP-MgCl2 was also shown to be a safe and effective 
vasodilator in children with PAH associated with con-
genital heart disease, as evidenced by a reduction in 
PAP and PVR without major systemic adverse effects 
(Table).75
Interestingly, in isolated intrapulmonary arteries, nei-
ther ATP-induced relaxation76 nor UTP-induced vaso-
constriction was different between healthy swine and 
PH swine exposed to hypoxia for 3 days.77 Surprisingly, 
ATP induced vasoconstriction in both pulmonary ar-
teries from broiler chicken with PH induced by excess 
tryptophan and control.78 The dinucleotide Up4A, which 
contains both a purine and a pyrimidine, induced con-
traction in healthy rat pulmonary arteries via P2YR,79,80 
but the effect of Up4A on pulmonary vasculature in PH 
has not been investigated to date.
Few studies actually investigated the functional 
role of different P2R subtypes in pulmonary vascular 
remodeling in PH. It has been reported that ATP or 
the P2Y11R agonist β-NAD induced a survival response 
and increased cell viability in healthy ECs, whereas the 
ATP-induced effect on survival and viability was not 
present in ECs when P2Y11R was knocked down.
19 
Furthermore, knockdown of P2Y11R in itself also de-
creased the survival capacity of healthy ECs and in-
creased vulnerability to serum starvation-induced 
apoptosis.19 More important, knockdown of P2Y11R in 
ECs derived from patients with PAH also sensitized the 
cells to apoptosis and decreased the cell viability.19
In a rat model of monocrotaline-induced PH, 
P2X7R expression in the pulmonary arterial smooth 
muscle layer was markedly increased (Figure  3).15 
Long-term treatment with the selective P2X7R an-
tagonist A-740003 reversed pulmonary vascular 
remodeling in this PH model (Table).15 Although the 
mechanisms were not investigated in this study, im-
paired vasomotor function was restored in a model of 
subfailure overstretch injury in rat aorta by treatment 
with P2X7R antagonists or P2X7R/pannexin complex 
antagonists. In this study, P2X7R antagonism re-
duced stretch-induced ATP release, decreased p38 
mitogen-activated protein kinase phosphorylation, 
increased phosphorylation of the antiapoptotic pro-
tein Akt in aorta, and reduced tumor necrosis fac-
tor-α–stimulated caspase 3/7 activity in cultured rat 
vascular SMCs.81
Taken together, both vasodilator (to ATP) and va-
soconstrictor (to ADP and UTP) responses to nucleo-
tide-induced P2R activation have been observed in the 
pulmonary vasculature of healthy subjects as well as 
subjects with PH. On the basis of the existing data on the 
involvement of P2Rs in pulmonary vasculature (Figure 2), 
ADP-mediated vasoconstriction is likely through activa-
tion of P2Y1R and P2Y12R, whereas UTP-induced vascu-
lar contraction is via P2Y2R. The P2R subtypes activated 
by ATP, as well as whether their expression patterns 
change in PH, remain to be determined, although the 
presence of PH seems to sensitize to pulmonary vascu-
lature to the vasoactive effects of ATP.
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Changes in P2R in PH are not limited to the pulmo-
nary vasculature. In a rat model of hypobaric hypox-
ia-induced PH, P2X4R mRNA levels were exclusively 
increased in RV of the heart compared with other tis-
sues, including left ventricles of the heart, lung, liver, 
kidney, and brain.38 The increased mRNA levels of 
P2X4R were followed by increases in P2X4R protein in 
the RV and were larger after more prolonged exposure 
of animals to hypobaric hypoxia.38 These changes in 
P2X4R in the RV occurred simultaneously with the in-
crease in PAP and the development of the RV hyper-
trophy (Table).38 However, the functional implications of 
the increase in P2X4R in the RV require further inves-
tigations. A recent study investigating the therapeutic 
effect of P2X7R antagonism for PH showed that the 
novel P2X7R antagonist PKT100 attenuated RV hy-
pertrophy and improved RV contractility and survival 
in a mouse model of PH induced by bleomycin in-
dependently of effects on the pulmonary vasculature 
(Table).52 This new finding may add new information on 
the current treatment option, in which the significant 
improvement in pulmonary pressure does not affect 
mortality caused by RV failure.
Possible Purinergic Dysfunction in 
Pulmonary Venous Remodeling?
Patients with PH, including PAH with scleroderma, 
chronic thromboembolic PH, and pulmonary venous 
occlusive disease, often display pulmonary venous 
and venular remodeling.82–84 The walls of septal veins 
and preseptal venules also show SMC hyperplasia with 
abnormal contraction, which may contribute to the el-
evated PVR. Contrary to the vasodilator effect of ATP in 
the pulmonary arteries, ATP induces a concentration-
dependent contraction in pulmonary veins, which is 
inhibited by the nonselective P2R antagonist suramin 
and the P2Y2R antagonist AR-C118925 but not by 
the P2Y1R antagonist MRS2179.
85 The functional evi-
dence is in accordance with the exclusive expression 
of P2Y2R in SMCs within pulmonary veins.
85 Activation 
of phospholipase C-β and generation of intracellular 
Ca2+ oscillations may serve as post-PR mechanisms 
for ATP-induced contraction in pulmonary veins.85 
Therefore, it is of interest to study whether P2YR sign-
aling in pulmonary veins plays a significant role in the 
development of PH.
PURINERGIC DYSFUNCTION IN 
INFLAMMATION AND IMMUNITY
Inflammation and maladapted immune responses 
have been reported to be involved in the pathogenesis 
of P(A)H, as evidenced by histological studies of the 
lung, the presence of circulating autoantibodies, and 
high plasma levels of cytokines.3,86 Proinflammatory 
cytokines, such as interleukin-6, interleukin-13, 
tumor necrosis factor-α, and interleukin-1β, are in-
dependently associated with survival rate in patients 
with PAH, indicating that therapeutic drugs target-
ing inflammation would be beneficial to patients with 
PAH.87
The expression and function of PRs on inflam-
matory and immune cells have been extensively 
characterized.88,89 Activation of many PRs, including 
A1R, P2X7R, P2Y1R, and P2Y6R, generally results in 
proinflammatory responses.90–94 In a rat model of 
monocrotaline-induced PH, long-term treatment with 
P2X7R antagonist Brilliant Blue G effectively attenu-
ated inflammation by reducing the proinflammatory 
cytokines interleukin-1β and tumor necrosis factor-α 
through the p38/mitogen-activated protein kinase 
pathway, thereby reducing cell infiltration in the alve-
olar space.36 In another study using the same model, 
the selective P2X7R antagonist A-740003 reduced 
macrophage numbers and proinflammatory cytokine 
levels in bronchoalveolar lavage fluid through sup-
pression of the upregulation of NLRP3 inflammasome 
(Table).15 Recent findings demonstrated that con-
ditional deletion of A2BR in myeloid cells altered the 
phenotype of macrophages and attenuated the de-
velopment of fibrosis and inflammation (decreased in-
terleukin-6 concentrations in bronchoalveolar lavage 
fluid) in a mouse model of lung injury-induced PH.53 
Taken together, purinergic signaling might contribute 
to the proinflammatory phenotype in P(A)H, and inhi-
bition of these effects might contribute to therapeutic 
efficacy (Table).
POTENTIAL ROLE OF ERYTHROCYTE-
MEDIATED PURINERGIC SIGNALING 
IN PAH
In addition to immune cells, emerging data suggest 
that erythrocytes not only act as regulators of normal 
physiological function to maintain cardiovascular ho-
meostasis and integrity but also act as important trig-
gers for the development of various cardiovascular 
diseases.95–97 It is well known that erythrocytes deliver 
oxygen to body tissues, and interestingly, erythrocytes 
also serve as ATP pool. The 2 functions are interde-
pendent as ATP release from erythrocytes has been 
observed particularly under hypoxia, to precisely 
regulate tissue perfusion and vascular tone in both 
experimental animals and humans.16,17 This regulation 
of vascular function by erythrocyte-derived ATP has 
been proposed to be mediated via activation of vaso-
dilator P2Y1R on the vasculature.
9,16 In the pulmonary 
vasculature, oxygen acts as an important vasodilator, 
which is likely to be mediated via ATP and subsequent 
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activation of PRs, as both P1R and P2YR contribute 
to the oxygen-induced decrease in PAP in newborn 
lambs with PH.48 Further evidence for an interaction 
between oxygen and release of purines is that young 
healthy humans exposed to high altitude exhibited in-
creased circulating adenosine levels and ecto-5’-nu-
cleotidase activity, suggesting that ATP is increased 
at high altitude and ATP breakdown to adenosine is 
subsequently enhanced via ecto-5’-nucleotidase.41 
The increase in adenosine was associated with in-
creased erythrocyte 2,3-bisphosphoglycerate and 
oxygen releasing capacity.41 Mechanistic studies using 
A2BR knockout mice demonstrated that increased 
adenosine activates the erythrocyte A2BR–AMP kinase 
axis, resulting in increased 2,3-bisphosphoglycerate 
production and a shift in the relation between oxy-
gen tension and oxygen saturation, thereby enhanc-
ing oxygen release to reduce the hypoxic burden. This 
subsequently reduced inflammation and lung injury, 
reflected by decreased cell counts, albumin, and in-
terleukin-6 concentrations in bronchoalveolar lavage 
fluid.41 The same group further found that adenosine-
A2BR-protein kinase A–induced proteasome-mediated 
degradation of the equilibrative nucleoside transporter 
1 on erythrocytes is an important cellular purinergic 
signaling regulatory component to counteract hypoxic 
pulmonary vascular leakage and inflammation, and 
that erythrocytes with reduced equilibrative nucleoside 
transporter 1 retain a “hypoxic purinergic memory” for 
quicker adaptation to subsequent hypoxia (Table).42
ATP release from erythrocytes was significantly 
reduced in patients with PAH compared with healthy 
subjects when erythrocytes were challenged with ei-
ther mechanical (passing erythrocytes through filters) 
or pharmacological stimulation (incubation with cAMP 
analogue to increase cAMP level, a required process 
for ATP release from erythrocytes).32 Of interest, a 
prostacyclin analogue increases cAMP and ATP to 
a greater extent in erythrocytes of patients with PAH 
than in healthy subjects.33 Additional phosphodies-
terase-5 inhibition further increased ATP release from 
erythrocytes, indicating that common PAH therapeutic 
strategies synergistically induce release of this potent 
vasodilator from erythrocytes.33 The impaired release 
of ATP from erythrocytes of PAH may alter vascular PR 
signaling and result in vascular dysfunction. It is also 
worth mentioning that oxygen concentrations are likely 
to be higher in pulmonary veins than in arteries. Thus, 
ATP released from erythrocytes may be lower in the 
vein. This potential difference may also have impact on 
pulmonary venous function.
In addition to the reduced ATP release from 
erythrocytes, higher adenosine deaminase activity 
in pulmonary circulation of patients with PAH may 
account for the lower levels of adenosine in pulmo-
nary compared with systemic circulation (Figure 1).20 
Of interest, erythrocytes from a rat model of hemo-
lysis-associated PH released more adenosine de-
aminase into the pulmonary circulation to hydrolyze 
extracellular adenosine, suggesting that erythrocytes 
may be a source of adenosine deaminase (Table).49 
Altogether, these findings suggest that erythrocytes 
are important intermediaries to initiate/activate puri-
nergic signaling.
POTENTIAL INTERACTION WITH 
AIRWAY DISEASE
PRs are not only present in the vasculature but also 
on the airways, where their activation can induce 
bronchoconstriction and exert a proinflammatory ef-
fect. Hence, P2X7R activation not only exerts a pro-
inflammatory effect on the vasculature but also on 
the airways as its activation results in upregulation of 
ROCK1 in bronchial and alveolar epithelial cells.40,98 
Antagonists of this receptor may therefore have a dual 
beneficial effect on both airways and vasculature in 
PAH. Conversely, there is evidence to suggest that ac-
tivation of P1R and P2R by adenosine and ATP plays a 
detrimental role in airway diseases, including asthma, 
allergy, and chronic obstructive pulmonary disease.98,99 
Particularly, activation of the A2AR has been shown to 
induce bronchoconstriction in patients with asthma 
and chronic lung diseases.100,101 Furthermore, activa-
tion of this receptor may worsen the inflammation in 
patients with asthma.100 Hence, when evaluating thera-
peutic effects of adenosine and A2AR agonism in PH, 
potential detrimental effects on the airways should be 
carefully monitored, particularly in patients with chronic 
lung diseases, such as asthma and chronic obstructive 
pulmonary disease.
CONCLUSIONS AND PERSPECTIVES
Emerging observations have suggested a role of 
nucleot(s)ide-mediated purinergic signaling in the de-
velopment and progression of P(A)H. The ectonucleoti-
dase CD39 is an important enzyme regulating purine 
and pyrimidine degradation, thereby modulating P2R 
signaling. CD39 is downregulated on the pulmonary 
endothelium of patients with PAH, which may promote 
pulmonary vascular remodeling. Furthermore, eryth-
rocyte dysfunction in these patients decreases ATP 
release and consequent dysregulation of the hypoxia-
induced adenosine response may further contribute to 
the development of PAH and lung injury.
A2AR and A2BR, both members of the P1R family, 
play a role in regulation of pulmonary vascular tone, 
vascular remodeling, inflammation, and immunity, 
and have shown potential as therapeutic targets in 
experimental models (Figure 3). A2AR knockout mice 
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exhibited a PH phenotype, suggesting loss of function 
in this receptor may initiate the disease. New A2AR ag-
onists have been developed and tested in an animal 
model of PH with promising outcome. Although the 
A2AR agonist regadenoson has been applied in pa-
tients with PAH for a cardiac stress test, future clinical 
trials are needed to investigate a potential therapeutic 
role of A2AR activation in the treatment of patients with 
PAH. These trials need to be carefully monitored as 
A2AR activation may result in a proinflammatory effect 
and may induce dyspnea with bronchoconstriction.
From the P2R subtypes, P2X7R, P2Y1R, P2Y11R, 
and P2Y12R have been shown to play a role in pul-
monary vascular remodeling, inflammation, and/or 
vascular tone regulation in PAH (Figure 3). Given the 
multitude of receptor subtypes expressed in different 
cells of the pulmonary arteries and lung, it remains to 
be investigated which receptors play a key role in the 
development of PAH, and whether single receptor or 
multiple receptors need to be targeted at the same 
time for the most effective therapy. This far, P2X7R in-
hibition has been shown to exert anti-inflammatory and 
antiremodeling effects on both the vasculature and the 
airways and to reduce RV hypertrophy, suggesting that 
the P2X7R may serve as a therapeutic target (Figure 3). 
Another important limitation to date is that there is lim-
ited knowledge about the molecular mechanisms in-
volved in the P2R signaling. Future studies in specific 
P2R knockout mice can be useful to elucidate these 
molecular mechanisms.
Altogether, existing evidence suggests that a role 
of altered purinergic signaling in the development and 
progression of P(A)H is plausible. Targeting nucleod(s)
ides and their regulated purinergic signaling may pro-
vide valuable possibilities for the treatment of PAH.
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